Related Experiment Videos
The prevention of diabetes-associated birth defects
E A Reece1, S Gabrielli, M Abdalla
1Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.
Insights
Diabetic mothers can reduce birth defects in infants by achieving optimal metabolic control before and during early pregnancy. Arachidonic acid shows promise for preventing diabetes-related embryopathy.
Area of Science:
- Obstetrics and Gynecology
- Developmental Biology
- Endocrinology
Background:
- Infants born to diabetic mothers have a high rate of birth defects, posing significant financial and psychosocial burdens.
- These malformations originate in early pregnancy and are linked to the maternal metabolic environment.
- Multiple factors likely contribute to the development of these defects.
Purpose of the Study:
- To investigate strategies for reducing birth defects in infants of diabetic mothers.
- To evaluate the impact of maternal metabolic control on embryogenesis.
- To explore the potential of arachidonic acid in preventing diabetes-related embryopathy.
Main Methods:
- Review of epidemiologic, clinical, and experimental studies.
- Analysis of the effects of periconceptual and first-trimester metabolic control in diabetic pregnancies.
- Examination of experimental data on arachidonic acid's role in preventing embryopathy.
Main Results:
- Optimal maternal metabolic control during the periconceptual period and first trimester significantly reduces malformation rates.
- Delaying conception until metabolic control is achieved is recommended for diabetic women.
- Arachidonic acid has emerged as a potential agent for pharmacologic prophylaxis against diabetes-related embryopathy.
Conclusions:
- Achieving optimal metabolic control before and during early pregnancy is crucial for preventing birth defects in infants of diabetic mothers.
- Diabetic women should consider delaying pregnancy until satisfactory metabolic status is attained.
- Arachidonic acid warrants further investigation as a preventive measure for diabetes-related embryopathy.
Abstract:
Birth defects among infants of diabetic mothers convey a major financial and sociologic burden to society notwithstanding the psychologic impact to the patients and families. Epidemiologic, clinical, and experimental studies indicate that these malformations occur in early pregnancy, are influenced by the abnormal maternal metabolic milieu, and seem to result from a combination of more than one factor. Clinical and experimental studies, however, have demonstrated that optimal metabolic control achieved in the periconceptual period and maintained throughout the first trimester of pregnancy results in a significant reduction in the malformation rate among offspring of diabetic mothers. In this light, diabetic women contemplating pregnancy should be encouraged to delay conception until satisfactory metabolic control is achieved so that embryogenesis may occur in an optimal metabolic milieu. The experimental use of arachidonic acid in the prevention of diabetes-related embryopathy is a new and potentially valuable tool. It extends the spectrum of available methods for prevention and deserves further study as a potential agent for pharmacologic prophylaxis.